Bunker Island Lighthouse near Yarmouth · Photo: Gordon Leggett · CC BY-SA 4.0
AbbVie to discontinue Humira 40 mg adalimumab on Oct 30
AbbVie reports its Humira (adalimumab) 40 mg solution for subcutaneous injection, in pre-filled syringe and pen form, is to be discontinued on Oct 30, 2026, for business reasons.
Humira is a widely used biologic for arthritis, psoriasis and inflammatory bowel disease — patients and prescribers should confirm the switch to biosimilars or other alternatives.
